CPT1C

Across TCGA pan-cancer cohorts, CPT1C mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CPT1C data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CPT1C mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CPT1C expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, UCEC, and LUAD are the cancer types where CPT1C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	1.000	0.862	.003	5	view →
UCEC	DFS	Median	II,III,IV	0.331	1.000	.045	4	view →
LUAD	OS	Tertile	All	0.956	1.000	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CPT1C–LSCC (DFS)

Open the LSCC breakdown →